You have 9 free searches left this month | for more free features.

refractory Acute Myeloid Leukemia

Showing 1 - 25 of >10,000

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Acute Myeloid Leukemia Refractory, Acute Myeloid Leukemia, in Relapse Trial in Xuzhou (anti Tim-3/CD123 CAR-T cell therapy)

Recruiting
  • Acute Myeloid Leukemia Refractory
  • Acute Myeloid Leukemia, in Relapse
  • anti Tim-3/CD123 CAR-T cell therapy
  • Xuzhou, Jiangsu, China
    Kailin Xu
Nov 4, 2023

Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory Trial (CB-012)

Not yet recruiting
  • Acute Myeloid Leukemia, in Relapse
  • Acute Myeloid Leukemia Refractory
  • (no location specified)
Nov 9, 2023

Acute Myeloid Leukemia, Blastic Plasmacytoid Dendritic Cell Tumor (BPDCN), Relapse Leukemia Trial in Taiyuan (CD123 targeted

Recruiting
  • Acute Myeloid Leukemia
  • +3 more
  • CD123 targeted CAR-NK cells
  • Taiyuan, Shanxi, China
    Shanxi Bethune Hospital
Aug 28, 2023

Relapsed/Refractory Acute Myeloid Leukemia Trial in Hangzhou (B7-H3 target, CAR gene modified gdT cell injection)

Recruiting
  • Relapsed/Refractory Acute Myeloid Leukemia
  • B7-H3 target, CAR gene modified gdT cell injection
  • Hangzhou, Zhejiang, China
    The First Affiliated Hospital, Zhejiang University School of Med
Feb 15, 2023

Acute Myeloid Leukemia, High-Risk and Very High-Risk MDS Trial (SGR-2921)

Not yet recruiting
  • Acute Myeloid Leukemia
  • High-Risk and Very High-Risk Myelodysplastic Syndromes
  • (no location specified)
Jul 25, 2023

AML, AML With Mutated NPM1, Hematologic Malignancy Trial (Ziftomenib, Fludarabine, Idarubicin)

Not yet recruiting
  • AML
  • +11 more
  • (no location specified)
Aug 14, 2023

Relapsed or Refractory Acute Myeloid Leukemia Trial in Taiyuan (Selinexor, Homoharringtonine, Daunorubicin)

Recruiting
  • Relapsed or Refractory Acute Myeloid Leukemia
  • Taiyuan, Shanxi, China
    Tao Wang
Feb 9, 2023

Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory, Granulocytic Sarcoma Trial in Winston-Salem (drug,

Not yet recruiting
  • Acute Myeloid Leukemia, in Relapse
  • +2 more
  • CPI 613
  • +3 more
  • Winston-Salem, North Carolina
    Wake Forest Baptist Comprehensive Cancer Center
May 10, 2023

Relapsed/Refractory Acute Myeloid Leukemia Trial in Hefei (gdT cell injection targeting B7-H3 chimeric antigen receptor)

Recruiting
  • Relapsed/Refractory Acute Myeloid Leukemia
  • gdT cell injection targeting B7-H3 chimeric antigen receptor
  • Hefei, Anhui, China
    PersonGen Anke Cellular Therapeutice Co., Ltd.
Jan 31, 2023

Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Refractory Acute

Active, not recruiting
  • Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
  • +2 more
  • Duarte, California
    City of Hope Medical Center
Jan 4, 2023

Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia Trial (UAE Inhibitor TAK-243)

Not yet recruiting
  • Myelodysplastic Syndrome
  • +4 more
  • UAE Inhibitor TAK-243
  • (no location specified)
Oct 20, 2022

Acute Myeloid Leukemia Refractory Trial in Lyon (NP137, Azacitidine Injection, Venetoclax)

Recruiting
  • Acute Myeloid Leukemia Refractory
  • Lyon, France
    Centre Léon Bérard
Nov 30, 2023

Acute Myeloid Leukemia Trial in Cincinnati (CIML-NK Cells)

Recruiting
  • Acute Myeloid Leukemia
  • CIML-NK Cells
  • Cincinnati, Ohio
    Cincinnati Children's Hospital Medical Center
Jan 4, 2023

Relapsed/Refractory Acute Myeloid Leukemia Trial in Beijing

Recruiting
  • Relapsed/Refractory Acute Myeloid Leukemia
  • Azacytidine;Cytarabine;Aclacinomycin;Chidamide;Venetoclax;Granulocyte colony-stimulating factor
  • Best-Available Therapy(BAT) Regimen
  • Beijing, Beijing, China
    Chinese PLA General Hospital
Oct 10, 2023

Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) Trial in China (BL-M11D1)

Not yet recruiting
  • Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)
  • Hefei, Anhui, China
  • +7 more
Jun 27, 2023

Leukemia, Myeloid, Acute Trial in Guangzhou, Hangzhou (BG1805)

Not yet recruiting
  • Leukemia, Myeloid, Acute
  • BG1805
  • Guangzhou, Guangdong, China
  • +2 more
Nov 1, 2023

Relapsed/Refractory Acute Myeloid Leukemia Trial (LILRB4 STAR-T cells)

Not yet recruiting
  • Relapsed/Refractory Acute Myeloid Leukemia
  • LILRB4 STAR-T cells
  • (no location specified)
Sep 16, 2022

Acute Myeloid Leukemia Trial in Valencia (AFM28)

Recruiting
  • Acute Myeloid Leukemia
  • Valencia, Spain
    Hospital Universitari i Politècnic La Fe
Apr 5, 2023

Acute Myeloid Leukemia, Recurrent Adult Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia Trial in Duarte (Anti-CD33 CAR

Not yet recruiting
  • Acute Myeloid Leukemia
  • +3 more
  • Anti-CD33 CAR T-cells
  • Lymphodepletion Therapy
  • Duarte, California
    City of Hope Medical Center
Jan 3, 2023

Hematopoietic and Lymphoid Cell Tumor, Recurrent Acute Biphenotypic Leukemia, Recurrent Acute Myeloid Leukemia Trial in Houston

Recruiting
  • Hematopoietic and Lymphoid Cell Neoplasm
  • +6 more
  • Houston, Texas
    M D Anderson Cancer Center
Dec 31, 2022

Acute Myeloid Leukemia Trial in Beijing, Tianjin (LCAR-AMDR Cells Product)

Recruiting
  • Acute Myeloid Leukemia
  • LCAR-AMDR Cells Product
  • Beijing, Beijing, China
  • +1 more
Jan 28, 2023

Leukemia Trial in California City, Chicago, Houston (GDX012, Chemotherapy Agents)

Not yet recruiting
  • Leukemia
  • California City, California
  • +2 more
May 24, 2023

Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia Trial in Baltimore, Buffalo (Gemtuzumab Ozogamicin,

Recruiting
  • Recurrent Acute Myeloid Leukemia
  • Refractory Acute Myeloid Leukemia
  • Gemtuzumab Ozogamicin
  • +4 more
  • Baltimore, Maryland
  • +1 more
Dec 13, 2022

Acute Myeloid Leukemia, MDS Trial in United States (GLB-001)

Recruiting
  • Acute Myeloid Leukemia
  • Myelodysplastic Syndromes
  • Duarte, California
  • +3 more
Nov 21, 2023